# CLN3

## Overview
The CLN3 gene encodes a transmembrane protein known as CLN3 lysosomal/endosomal transmembrane protein, or battenin, which is primarily localized to lysosomes and endosomes. This protein plays a critical role in maintaining lysosomal homeostasis and is involved in various cellular processes, including endocytic trafficking, autophagy, and ion channel regulation. The CLN3 protein is characterized by its hydrophobic nature and multiple transmembrane domains, classifying it as a multipass transmembrane protein. It interacts with several proteins, such as Rab GTPases and cytoskeletal components, to facilitate vesicular movement and membrane dynamics, which are essential for cellular functions like migration and synaptic activity. Mutations in the CLN3 gene are linked to juvenile neuronal ceroid lipofuscinosis (JNCL), a severe neurodegenerative disorder, underscoring the gene's clinical significance (Cotman2021CLN3).

## Structure
The CLN3 protein, encoded by the CLN3 gene, is a hydrophobic membrane protein consisting of 438 amino acids. It is predicted to have six transmembrane domains, with both the N- and C-termini facing the cytosol, suggesting a type III membrane protein structure (Cotman2012The; Kyttälä2006Functional; Mirza2019The). The protein's secondary structure is primarily composed of transmembrane and low complexity cytosolic or luminal spans (Mirza2019The).

CLN3 shares distant sequence similarity with the major facilitator superfamily (MFS), which includes various transporters, although it is predicted to have fewer transmembrane domains than typical MFS members (Cotman2012The). The protein may form homodimers, although this is not confirmed in its endogenous form (Cotman2012The).

Post-translational modifications of CLN3 include N-glycosylation, with two confirmed N-glycosylation sites, N71 and N310, located in lumenal regions (Kyttälä2004Two). The protein also undergoes prenylation, specifically farnesylation, which aids in membrane attachment (Mirza2019The). Several splice variants of CLN3 exist, resulting in proteins of varying lengths and potentially affecting their function and localization (Cotman2012The; Mirza2019The).

## Function
The CLN3 gene encodes a multipass transmembrane protein primarily localized to endosomes and lysosomes, playing a crucial role in maintaining lysosomal homeostasis and function in healthy human cells (Cotman2021CLN3; Jarvela1998Biosynthesis). CLN3 is involved in endocytic trafficking, autophagy, and the regulation of ion channels, which are essential for cellular waste processing and recycling (Cotman2021CLN3). It interacts with cytoskeletal proteins and small GTPases, influencing vesicular movement and membrane dynamics, which are vital for processes such as cell migration and synaptic function (Cotman2021CLN3).

In neurons, CLN3 is implicated in the polarized sorting and transport of organelles, such as lysosomes, which are crucial for cellular degradation processes and maintaining neuronal health (Cotman2021CLN3). In epithelial cells, it plays a role in phagocytosis, endocytosis, and osmoregulation, contributing to the integrity and function of these cells (Cotman2021CLN3). CLN3 also interacts with proteins involved in lysosomal sorting and trafficking, such as Rab1a and Rab7A, ensuring proper lysosomal enzyme function and autophagosome-lysosome fusion (Cotman2021CLN3). These functions are critical for cellular homeostasis and the prevention of neurodegenerative disorders.

## Clinical Significance
Mutations in the CLN3 gene are primarily associated with juvenile neuronal ceroid lipofuscinosis (JNCL), also known as Batten disease. This is a neurodegenerative disorder characterized by progressive vision loss, seizures, and cognitive decline, typically beginning in childhood (Lebrun2011Analysis; Kousi2011Update; Mole1999Molecular). The most common mutation is a 1-kb deletion affecting exons 7 and 8, which accounts for a significant majority of disease cases. This deletion leads to a truncated protein that retains some function but is unable to traffic out of the endoplasmic reticulum, contributing to the disease pathology (PurzyckaOlewiecka2022Deterioration; Kousi2011Update).

The clinical presentation of CLN3 disease includes early visual impairment, followed by motor and cognitive decline, seizures, and eventual premature death, typically in the third decade of life (Lebrun2011Analysis; Kousi2011Update). Variants of the disease with slower progression have been identified, often associated with compound heterozygous mutations, such as a combination of the 1-kb deletion and a missense mutation (Kousi2011Update; Mole1999Molecular). These missense mutations may allow for some residual protein function, resulting in a milder disease course (Kitzmuller2007A).

## Interactions
The CLN3 protein, also known as battenin, is involved in various protein interactions that are crucial for its function in lysosomal and endosomal processes. CLN3 interacts with the microtubule-binding protein Hook1, which suggests a role in mediating the dissociation of Hook1 from microtubules, as overexpression of CLN3 leads to Hook1 aggregation (Luiro2004Interconnections). It also interacts with Rab GTPases, including Rab7, Rab9, and Rab11, indicating its involvement in membrane trafficking events (Luiro2004Interconnections).

CLN3 has been shown to interact with Rab7A, a small GTPase involved in endosomal trafficking. This interaction is crucial for the steady-state localization of lysosomes and the compartmentalization of Rab7 (Yasa2020CLN3; UusiRauva2012Neuronal). Mutations in CLN3, such as R334H and V330F, increase its interaction with Rab7A, potentially affecting Rab7A's membrane retention and cycling (Yasa2020CLN3).

CLN3 also interacts with the Na+, K+ ATPase complex and the cytoskeletal protein fodrin, suggesting a role in regulating the plasma membrane fodrin cytoskeleton and the association of Na+, K+ ATPase with the plasma membrane (UusiRauva2008Novel). These interactions link CLN3 to cytoskeletal and endosomal functions, which may contribute to the pathogenesis of Batten disease.


## References


[1. (Kyttälä2004Two) Aija Kyttälä, Gudrun Ihrke, Jouni Vesa, Michael J. Schell, and J. Paul Luzio. Two motifs target batten disease protein cln3 to lysosomes in transfected nonneuronal and neuronal cells. Molecular Biology of the Cell, 15(3):1313–1323, March 2004. URL: http://dx.doi.org/10.1091/mbc.E03-02-0120, doi:10.1091/mbc.e03-02-0120. This article has 163 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.E03-02-0120)

[2. (Lebrun2011Analysis) Anne-Hélène Lebrun, Parisa Moll-Khosrawi, Sandra Pohl, Georgia Makrypidi, Stephan Storch, Dirk Kilian, Thomas Streichert, Benjamin Otto, Sara E. Mole, Kurt Ullrich, Susan Cotman, Alfried Kohlschütter, Thomas Braulke, and Angela Schulz. Analysis of potential biomarkers and modifier genes affecting the clinical course of cln3 disease. Molecular Medicine, 17(11–12):1253–1261, August 2011. URL: http://dx.doi.org/10.2119/molmed.2010.00241, doi:10.2119/molmed.2010.00241. This article has 46 citations and is from a peer-reviewed journal.](https://doi.org/10.2119/molmed.2010.00241)

[3. (Cotman2021CLN3) Susan L. Cotman and Stéphane Lefrancois. Cln3, at the crossroads of endocytic trafficking. Neuroscience Letters, 762:136117, September 2021. URL: http://dx.doi.org/10.1016/j.neulet.2021.136117, doi:10.1016/j.neulet.2021.136117. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.neulet.2021.136117)

[4. (Luiro2004Interconnections) K. Luiro. Interconnections of cln3, hook1 and rab proteins link batten disease to defects in the endocytic pathway. Human Molecular Genetics, 13(23):3017–3027, September 2004. URL: http://dx.doi.org/10.1093/hmg/ddh321, doi:10.1093/hmg/ddh321. This article has 120 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddh321)

[5. (Yasa2020CLN3) Seda Yasa, Graziana Modica, Etienne Sauvageau, Abuzar Kaleem, Guido Hermey, and Stephane Lefrancois. Cln3 regulates endosomal function by modulating rab7a–effector interactions. Journal of Cell Science, March 2020. URL: http://dx.doi.org/10.1242/jcs.234047, doi:10.1242/jcs.234047. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.234047)

[6. (Mole1999Molecular) Sara E. Mole, Hannah M. Mitchison, and Patricia B. Munroe. Molecular basis of the neuronal ceroid lipofuscinoses: mutations incln1,cln2,cln3, andcln5. Human Mutation, 14(3):199–215, 1999. URL: http://dx.doi.org/10.1002/(SICI)1098-1004(1999)14:3<199::AID-HUMU3>3.0.CO;2-A, doi:10.1002/(sici)1098-1004(1999)14:3<199::aid-humu3>3.0.co;2-a. This article has 93 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/(SICI)1098-1004(1999)14:3)

[7. (Kyttälä2006Functional) Aija Kyttälä, Ulla Lahtinen, Thomas Braulke, and Sandra L. Hofmann. Functional biology of the neuronal ceroid lipofuscinoses (ncl) proteins. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1762(10):920–933, October 2006. URL: http://dx.doi.org/10.1016/j.bbadis.2006.05.007, doi:10.1016/j.bbadis.2006.05.007. This article has 74 citations.](https://doi.org/10.1016/j.bbadis.2006.05.007)

[8. (UusiRauva2012Neuronal) Kristiina Uusi-Rauva, Aija Kyttälä, Rik van der Kant, Jouni Vesa, Kimmo Tanhuanpää, Jacques Neefjes, Vesa M. Olkkonen, and Anu Jalanko. Neuronal ceroid lipofuscinosis protein cln3 interacts with motor proteins and modifies location of late endosomal compartments. Cellular and Molecular Life Sciences, 69(12):2075–2089, January 2012. URL: http://dx.doi.org/10.1007/s00018-011-0913-1, doi:10.1007/s00018-011-0913-1. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-011-0913-1)

[9. (Kousi2011Update) Maria Kousi, Anna-Elina Lehesjoki, and Sara E. Mole. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Human Mutation, 33(1):42–63, November 2011. URL: http://dx.doi.org/10.1002/humu.21624, doi:10.1002/humu.21624. This article has 264 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21624)

[10. (Jarvela1998Biosynthesis) I. Jarvela, M. Sainio, T. Rantamaki, V. M. Olkkonen, O. Carpen, L. Peltonen, and A. Jalanko. Biosynthesis and intracellular targeting of the cln3 protein defective in batten disease. Human Molecular Genetics, 7(1):85–90, January 1998. URL: http://dx.doi.org/10.1093/hmg/7.1.85, doi:10.1093/hmg/7.1.85. This article has 140 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/7.1.85)

[11. (UusiRauva2008Novel) Kristiina Uusi-Rauva, Kaisu Luiro, Kimmo Tanhuanpää, Outi Kopra, Pablo Martín-Vasallo, Aija Kyttälä, and Anu Jalanko. Novel interactions of cln3 protein link batten disease to dysregulation of fodrin–na+, k+ atpase complex. Experimental Cell Research, 314(15):2895–2905, September 2008. URL: http://dx.doi.org/10.1016/j.yexcr.2008.06.016, doi:10.1016/j.yexcr.2008.06.016. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2008.06.016)

[12. (PurzyckaOlewiecka2022Deterioration) Joanna Karolina Purzycka-Olewiecka, Katarzyna Hetmańczyk-Sawicka, Tomasz Kmieć, Dominika Szczęśniak, Joanna Trubicka, Maciej Krawczyński, Maciej Pronicki, and Agnieszka Ługowska. Deterioration of visual quality and acuity as the first sign of ceroid lipofuscinosis type 3 (cln3), a rare neurometabolic disease. Metabolic Brain Disease, 38(2):709–715, December 2022. URL: http://dx.doi.org/10.1007/s11011-022-01148-5, doi:10.1007/s11011-022-01148-5. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11011-022-01148-5)

[13. (Cotman2012The) Susan L Cotman and John F Staropoli. The juvenile batten disease protein, cln3, and its role in regulating anterograde and retrograde post-golgi trafficking. Clinical Lipidology, 7(1):79–91, February 2012. URL: http://dx.doi.org/10.2217/clp.11.70, doi:10.2217/clp.11.70. This article has 73 citations and is from a peer-reviewed journal.](https://doi.org/10.2217/clp.11.70)

[14. (Kitzmuller2007A) C. Kitzmuller, R. L. Haines, S. Codlin, D. F. Cutler, and S. E. Mole. A function retained by the common mutant cln3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis. Human Molecular Genetics, 17(2):303–312, October 2007. URL: http://dx.doi.org/10.1093/hmg/ddm306, doi:10.1093/hmg/ddm306. This article has 64 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddm306)

[15. (Mirza2019The) Myriam Mirza, Anna Vainshtein, Alberto DiRonza, Uma Chandrachud, Luke J. Haslett, Michela Palmieri, Stephan Storch, Janos Groh, Niv Dobzinski, Gennaro Napolitano, Carolin Schmidtke, and Danielle M. Kerkovich. The cln3 gene and protein: what we know. Molecular Genetics &amp; Genomic Medicine, September 2019. URL: http://dx.doi.org/10.1002/mgg3.859, doi:10.1002/mgg3.859. This article has 53 citations.](https://doi.org/10.1002/mgg3.859)